Source comparison
CJC-1295 Pharmacology Studies: Research-Grade vs Clinical-Grade Comparison
DAC Modification Present Yes. Covalent albumin binding confirmed Yes. Includes maleimidoproprionic acid linker No. Lacks albumin-binding group Only DAC-modified CJC-1295 replicates the extended half-life and sustained GH response documented in pharmacology stu
This comparison does not assign a generated winner or score.
- DAC Modification Present
- Yes. Covalent albumin binding confirmed
- Yes. Includes maleimidoproprionic acid linker
- No. Lacks albumin-binding group
- Only DAC-modified CJC-1295 replicates the extended half-life and sustained GH response documented in pharmacology studies
- Half-Life
- 6–8 days (measured via plasma immunoreactivity)
- Expected 6–8 days (structure identical to clinical compound)
- <30 minutes (equivalent to native GHRH)
- Modified CJC-1295 without DAC is pharmacologically distinct. Dosing protocols from CJC-1295 studies do not apply
- Dosing Frequency
- Twice weekly or weekly
- Twice weekly or weekly recommended
- Multiple daily doses required
- Research-grade CJC-1295 with DAC allows practical once- or twice-weekly protocols validated in human trials
- IGF-1 Elevation Duration
- 10–14 days post-injection (Phase I data)
- Expected 10–14 days (same molecular structure)
- 2–4 hours maximum
- Sustained IGF-1 response requires DAC modification. Modified CJC-1295 produces transient elevation only
- Purity Standard
- >98% (clinical-grade synthesis)
- >98% (third-party verified via HPLC/MS)
- Variable (supplier-dependent)
- Research-grade CJC-1295 from verified suppliers matches clinical purity. Modified versions often show lower purity due to degradation